Buprenex 与 Levaquin (Levofloxacin Oral Solution)
Buprenex 与 Levaquin (Levofloxacin Oral Solution)互相作用以及同时服用的可能性。
在该服务的官方手册中,已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果,或起到良好效果。具体联合用药问题,需遵从医嘱。
用户:用左氧氟沙星一起丁丙诺啡可以增加风险的一个不规则的心脏的节奏可能是严重的和潜在威胁生命,尽管它是一个比较罕见的副作用。 你可以更容易受如果你有一个称为先天性心脏病长期脱综合症,其他心脏疾病,导异常,或电解质紊乱(例如,镁或钾的损失,由于严重或长期腹泻或者呕吐)。 谈谈你的医生如果你有任何疑问或关切的问题。 你应该立即寻求医疗照顾,如果你开发的突然眩晕、头晕、眩晕、呼吸急促、或心悸在处理与这些药物,无论是共同或单独的。 重要的是要告诉你的医生关于所有其他药物的使用,包括维生素和草药。 不停止使用任何药物,没有第一个说你的医生。
医界专家:监测:某些种药物,包括左氧氟沙星,诺氟沙星、和氧氟沙星,可能造成的剂量相关的延长夸脱间间隔在一些患者。 从理论上讲,共同给予与其他药剂,可以延长的建间间隔可能会导致累加效应和风险增加的心律失常包括心动de扭转性和突然死亡。 在上市后监控,罕见的情况下的心动de扭转性和室性心动过速已经报道的患者在服用左氧氟沙星,诺氟沙星、和氧氟沙星。 的左氧氟沙星的情况主要涉及的患者的基本医疗的条件或考虑伴随药物可能已经缴款方式。 在一般情况下,危险的个人的代理人或一组合剂,导致心律失常的协会与建延长很大程度上是不可预测,但可以通过增加某些基本风险因素,诸如先天性长夸脱综合症、心脏病、以及电解质紊乱(例如,低钾,镁血症). 此外,药物诱发的夸脱的延长取决于特定的药物(s)参与和剂量(s)的药物(s)。
管理:虽然风险的一个严重的相互作用可能是低的,我们必须小心谨慎建议,如果左氧氟沙星,诺氟沙星,或氧氟沙星的是结合使用其他药物,可以延长夸脱的时间间隔。 由于幅度QTc延长的增加而增加的等离子浓度的诺酮,推荐剂量和静脉输液率不应超过。 患者应建议寻求迅速的医疗注意,如果他们遇到的症状可能表明发生心动de扭转性,例如头晕、头晕、昏厥,心悸,不规则的心律、呼吸急促,或者昏厥。
- Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.
- Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002): 455-64
- Falagas ME, Rafailidis PI, Rosmarakis ES "Arrhythmias associated with fluoroquinolone therapy." Int J Antimicrob Agents 29 (2007): 374-9
- Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003): 292-303
- Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999): 528-9
- Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002): 269-77
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001): 32-7
- Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B "Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?" South Med J 99 (2006): 52-6
- Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones." Br Med J 322 (2001): 46-7
- Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001): 1468-72
- "Product Information. Floxin (ofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.
- Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG "QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine." Ann Pharmacother 39 (2005): 543-6
- Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004): 1091-124
- Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19
- Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001): 122-6
- Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003): 2317-20
- Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9
- Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002): 663-8; discussion 668-72
非专利名称: buprenorphine
品牌: Buprenex, Belbuca, Probuphine, Butrans, Sublocade, Subutex
同义词: Buprenex (injection - Buprenex)
非专利名称: levofloxacin
品牌: Levaquin
同义词: Levaquin
在药物相容性与互相作用的检测过程中使用下列的信息来源:Drugs.com, Rxlist.com, Webmd.com, Medscape.com。
- Buprenex-Levaquin (Levofloxacin Tablets)
- Buprenex-Levaquin injection
- Buprenex-Levaquin Intravenous
- Buprenex-Levaquin Oral Solution
- Buprenex-Levatio Patch
- Buprenex-Levatol
- Levaquin (Levofloxacin Oral Solution)-Buprenex injection - Buprenex
- Levaquin (Levofloxacin Oral Solution)-Buprenorphine
- Levaquin (Levofloxacin Oral Solution)-Buprenorphine and Naloxone
- Levaquin (Levofloxacin Oral Solution)-Buprenorphine and Naloxone Buccal Film
- Levaquin (Levofloxacin Oral Solution)-Buprenorphine and naloxone oral/sublingual
- Levaquin (Levofloxacin Oral Solution)-Buprenorphine and Naloxone Sublingual Film